NCT07911423Not yet recruiting
Immunotherapy in Neuroendocrine Carcinoma of the Cervix
Efficacy of Immunotherapy in Neuroendocrine Carcinoma of the Cervix: A Retrospective Study
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
This retrospective study reviews existing medical records. No new treatments or tests are given. The study asks how well immunotherapy worked for people with a rare cancer called neuroendocrine carcinoma of the cervix. Immunotherapy is a treatment that helps the body's immune system fight cancer. The investigators will review the records of approximately 150 participants treated with immunotherapy for this cancer. The study will evaluate: (1) how long participants lived without the cancer getting worse; (2) how long participants lived overall; (3) whether the cancer shrank or stopped growing; (4) what side effects occurred, especially immune-related side effects; and (5) whether certain tumor markers or different treatment plans made a difference. Participants will not be contacted or asked to complete any procedures. Only information already contained in medical records will be used. Names and other personal details will be removed to protect privacy. The study has been approved by the ethics committee at Peking Union Medical College Hospital. The results may help doctors choose the best treatment for patients with this rare cancer. Results will be shared in medical journals and at medical meetings. For patients and families: This study does not enroll new participants. Questions about this cancer or immunotherapy should be directed to a physician.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 10 Oct 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Neuroendocrine tumours, Cervical cancer
- NCT number
- NCT07911423
What you commit to
- Study type: Observational
- Planned participants: 150
- From 1 Nov 2026 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Did not meet all of the above inclusion criteria;
- Key clinical data severely missing, making it impossible to extract valid informationinformation.
Who the study is looking for
- Age ≥ 18 years at the time of diagnosis;
- Histopathologically confirmed diagnosis of neuroendocrine carcinoma of the cervix (NECC), including small cell type, large cell type, and mixed type;
- Received at least one cycle of immune checkpoint inhibitor-based therapy targeting the PD-1/PD-L1 pathway;
- Complete medical records, detailed treatment regimens, and available efficacy evaluation data;
Age in the registry: 18 years to 100 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.